Results 61 to 70 of about 21,448 (153)

Antipsychotic Use Among Intellectually Disabled Individuals With Rare Genetic Variants That Confer Risk for Schizophrenia

Journal of Intellectual Disability Research, Volume 70, Issue 4, Page 440-445, April 2026.
ABSTRACT Background Rare genetic variation can predispose individuals to the development of schizophrenia, with certain genes and copy number variants (CNVs) conferring risk at the exome/genome‐wide level. Despite this strong association, little is known about antipsychotic effectiveness and tolerability among individuals with most of these disorders ...
Mark Ainsley Colijn
wiley   +1 more source

Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence

Neuropsychiatric Disease and Treatment, 2011
Roger S McIntyre1,2,3,4, Jinju Yoon3, Jeanette M Jerrell5, Samantha S Liauw31Department of Psychiatry, University of Toronto, Toronto, ON, Canada; 2Department of Pharmacology, University of Toronto, Toronto, ON, Canada; 3Mood Disorders Psychopharmacology
McIntyre R, Yoon J, Jerrell JM, Liauw SS
doaj  

Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome

Scientific Reports, 2017
The dopamine partial agonist aripiprazole is increasingly used to treat pathologies for which other antipsychotics are indicated because it displays fewer side effects, such as sedation and depression-like symptoms, than other dopamine receptor ...
Alexandre Salvador, Yulia Worbe, Cécile Delorme, Giorgio Coricelli, Raphaël Gaillard, Trevor W. Robbins, Andreas Hartmann, Stefano Palminteri   +7 more
doaj   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment

British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 869-878, March 2026.
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro, Clémence Lacroix, Élisabeth Jouve, Élisabeth Frauger, Maryse Lapeyre‐Mestre, Joëlle Micallef   +5 more
wiley   +1 more source

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia

SAGE Open Medical Case Reports, 2017
Background: Schizophrenia is a chronic disease that requires long-term management with antipsychotics; however, an important barrier to the success of long-term treatment is drug noncompliance, which increases the risk of recurrence and hospitalization ...
Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Hideo Matsumoto, Katsunaka Mikami   +4 more
doaj   +1 more source

Behavioral Phenotype and Neuropsychological Profile of an Adult With Smith‐Magenis Syndrome due to a Previously Unreported RAI1 Mutation: A Case Report

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Smith‐Magenis Syndrome (SMS) is an uncommon genetic disorder caused by microdeletions of chromosome 17p11.2 including the RAI1 gene, or loss‐of‐function mutations that directly affect RAI1. Due to the involvement of RAI1 in neurodevelopment, SMS leads to typical pathologic features in the behavioral and physical phenotype that must be ...
Edgar Andrés Chavarría‐Martínez, Julen Arellano‐Sandúa, Ruth Arias‐Hidalgo, Ana Patiño‐García, Adrián Cano‐Prous   +4 more
wiley   +1 more source

Developing a Polygenic Risk Score for Weight Gain in People Treated for Psychosis—Application in a Real‐World Setting

Human Psychopharmacology: Clinical and Experimental, Volume 41, Issue 2, March 2026.
ABSTRACT Introduction Genetic factors are thought to play an important role in antipsychotic‐induced weight gain (AIWG). Polygenic risk scores (PRS) could provide a measure of genetic predisposition to antipsychotic drug induced weight gain (AIWG).We conducted a study to examine how a PRS, generated using SNPs, identified from a recent meta‐analysis ...
Adrian Heald, Yasitha Illangasekera, Camila Marcelino Loureiro, Mark Shakespeare, Adam Jameson, Adrian Phillipson, Gavin P. Reynolds, Caroline Dalton   +7 more
wiley   +1 more source

Aripiprazole reduces liver cell division.

PLoS ONE, 2020
Effects of aripiprazole on dopamine regulation are being tested as a treatment for patients with a dual diagnosis of schizophrenia and addictions, often cocaine dependence.
Tinkara Pirc Marolt, Barbara Kramar, Klara Bulc Rozman, Dušan Šuput, Irina Milisav   +4 more
doaj   +1 more source

Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder

JCPP Advances, Volume 6, Issue 1, March 2026.
This systematic review aimed to assess the current evidence on the efficacy and safety of Atomoxetine in common clinical symptoms of autism spectrum disorder (ASD) for children and adolescents. With limited studies available, there is a need for more high‐power studies for the use of Atomoxetine in children and adolescents with autism spectrum disorder.
Nihit Gupta, Daniel Boyes, Hunter Hanlon‐Taylor, Mayank Gupta   +3 more
wiley   +1 more source

Huntington's Disease and Huntington's Disease‐like 2 (HDL2) in Martinique

Movement Disorders Clinical Practice, Volume 13, Issue 3, Page 673-682, March 2026.
ABSTRACT Background Huntington's Disease‐like 2 (HDL2), caused by a CAG repeat expansion in JPH3, closely resembles HD. All reported HDL2 patients to date have some African ancestry. While both disorders exist in the Caribbean, their relative frequency and clinical characteristics remain largely unknown.
Ignacio Antolin‐Sanfeliz, Anna‐Gaelle Giguet‐Valard, Sophie Duclos, Cécile Cazeneuve, Chloé Angelini, Aïssatou Signaté, Russell L. Margolis, Cyril Goizet, Rémi Bellance   +8 more
wiley   +1 more source